Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imprime PGG and BTH1704 in advanced pancreatic cancer
NCT02132403Phase 1Terminated
- Sponsor
- University of Illinois Chicago
- Start
- Aug 2014
- Primary completion
- Apr 2015
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 1, open-label trial of odetiglucan and bth1704 in pancreatic cancer (PC), sponsored by University of Illinois Chicago. Started Aug 2014; status: terminated.
02
Drugs
odetiglucanbth1704
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT02132403.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02132403.